Merck Eyes Primary Care Opportunities Despite Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
Two of Merck’s potential near-term launches, suvorexant for insomnia and odanacatib for osteoporosis, will enter crowded markets dominated by generics, but executives at the Citi Global Health Care conference maintain that novel mechanisms of action will address unmet market opportunities.